Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I and IIa trial of KW-0761 in patients with HAM

Next Previous
X
Search
Trial Profile

Phase I and IIa trial of KW-0761 in patients with HAM

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Aug 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mogamulizumab (Primary)
  • Indications Spinal disorders; Tropical spastic paraparesis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

    • Most Recent Events

    • 01 Aug 2023 Results of post hoc analysis (from studies UMIN000019942 and UMIN000012655) assessing the therapeutic effect of mogamulizumab on gait function by comparing it with contemporary control data from a HAM/TSP patient registry published in the Brain
    • 08 Feb 2018 Results assessing safety, pharmacokinetics and efficacy published in the New England Journal of Medicine
    • 24 Sep 2015 Status changed from recruiting to active, no longer recruiting, as per University Hospital Medical Information Network - Japan record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top